Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

BTKi Acalabrutinib with anti-CD20 Obinutuzumab in Treatment-Naive and R/R CLL After 3-Year FollowUp Yielded High Responsive Durable Rates

452 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login